

WILLS EYE PUBLICATIONS LIST – JULY 2023

**A Wills Eye affiliation search function was used in PubMed to populate the list below. Any manuscripts published in July 2023 under a different affiliation and/or not present on PubMed was not included in this list. This list is also published in the Research section of the Wills Eye website at <https://www.willseye.org/research-2/publications/>.*

CORNEA

Cehelyk EK, Crespo MA, Syed ZA. Publication Rates of Registered Corneal Trials on ClinicalTrials.gov. Cornea. 2023 Jul 4. doi: 10.1097/ICO.0000000000003339. Epub ahead of print. PMID: 37404122. <https://pubmed.ncbi.nlm.nih.gov/37404122/>

Daher ND, Milman T, Syed ZA. Migratory subconjunctival cyst. J Fr Ophtalmol. 2023 Jul 4:S0181-5512(23)00279-6. doi: 10.1016/j.jfo.2023.01.039. Epub ahead of print. PMID: 37414670. <https://pubmed.ncbi.nlm.nih.gov/37414670/>

Marek S, Forbes G, Avery RA, Zanganeh T, Davidson S, DeCarlo E, Kumar P, **Hammersmith K.** Potential blindness from nutritional xerophthalmia in autistic patients. J AAPOS. 2023 Jul 14:S1091-8531(23)00138-6. doi: 10.1016/j.jaapos.2023.05.009. Epub ahead of print. PMID: 37453663. <https://pubmed.ncbi.nlm.nih.gov/37453663/>

Sadeghi E, **Mahmoudzadeh R, Garg SJ,** Nowroozzadeh MH. Ocular posterior segment complications following COVID-19 vaccination. Int Ophthalmol. 2023 Jul 11. doi: 10.1007/s10792-023-02795-y. Epub ahead of print. PMID: 37432598. <https://pubmed.ncbi.nlm.nih.gov/37432598/>

DIVERSITY

Haller JA. Apparently It's Still Thought Risky to Speak While Female. JAMA Ophthalmol. 2023 Jul 20. doi: 10.1001/jamaophthalmol.2023.3197. Epub ahead of print. PMID: 37471102. <https://pubmed.ncbi.nlm.nih.gov/37471102/>

GLAUCOMA

Bowd C, Belghith A, Rezapour J, Christopher M, Jonas JB, **Hyman L,** Fazio MA, Weinreb RN, Zangwill LM. Multimodal Deep Learning Classifier for Primary Open-angle Glaucoma Diagnosis Using Wide-field Optic Nerve Head Cube Scans in Eyes With and Without High Myopia. J Glaucoma. 2023 Jul 19. doi: 10.1097/IJG.0000000000002267. Epub ahead of print. PMID: 37523623. <https://pubmed.ncbi.nlm.nih.gov/37523623/>

Ramesh S, Shalaby WS, Myers JS, Katz LJ, Kolomeyer NN, Lee D, Razeghinejad R, Moster MR, Shukla AG. Evaluation of the Hypertensive Phase after Ahmed Glaucoma Valve Implantation in Neovascular Glaucoma. J Curr Glaucoma Pract. 2023 Apr-Jun;17(2):91-97. doi: 10.5005/jp-journals-10078-1406. PMID: 37485460; PMCID: PMC10357026. <https://pubmed.ncbi.nlm.nih.gov/37485460/>

Wong MK, Bowers ME, Ventimiglia J, **Niknam RM, Moster MR, Pro MJ, Dale E, Kolomeyer NN, Lee D, Zheng CX**. Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma. *J Glaucoma*. 2023 Jul 20. doi: 10.1097/IJG.0000000000002271. Epub ahead of print. PMID: 37523637. <https://pubmed.ncbi.nlm.nih.gov/37523637/>

OCULAR ONCOLOGY

Djulfbegovic M, Taylor Gonzalez DJ, Uversky VN, **Shields CL**, Karp CL. Intrinsic disorder may drive the interaction of PROS1 and MERTK in uveal melanoma. *Int J Biol Macromol*. 2023 Jul 26;250:126027. doi: 10.1016/j.ijbiomac.2023.126027. Epub ahead of print. PMID: 37506796. <https://pubmed.ncbi.nlm.nih.gov/37506796/>

Negretti GS, Zeiger JS, Cherkas E, Shields CL. Posterior scleritis following COVID-19 vaccination or infection simulating uveal melanoma in 8 consecutive patients. *Eye (Lond)*. 2023 Jul 8. doi: 10.1038/s41433-023-02656-z. Epub ahead of print. PMID: 37422535. <https://pubmed.ncbi.nlm.nih.gov/37422535/>

Shields CL, Samuelson AG, Oh GJ, DeSimone JD, Sajjadi ZL, Bas Z, Kalafatis NE, Lally SE, Shields JA, Dockery PW. Conditional Metastasis of Uveal Melanoma in 8091 Patients over Half-Century (51 Years) by Age Group: Assessing the Entire Population and the Extremes of Age. *Invest Ophthalmol Vis Sci*. 2023 Jul 3;64(10):7. doi: 10.1167/iovs.64.10.7. PMID: 37418273; PMCID: PMC10337788. <https://pubmed.ncbi.nlm.nih.gov/37418273/>

OCULOPLASTIC & ORBITAL SURGERY

Smartz TM, Jabori SK, **Djulfbegovic MB**, Watane A, Sayegh Y, Lyons N, Singh DP. Correlation Between Altmetric Scores and Citation Count in 4 High-Impact Plastic Surgery Journals. *Aesthet Surg J*. 2023 Jul 20:sjad239. doi: 10.1093/asj/sjad239. Epub ahead of print. PMID: 37474313. <https://pubmed.ncbi.nlm.nih.gov/37474313/>

RETINA

Akhlaq A, Williams D, Clark WL, Khan H, Khanani AM, Walden L, Awh C, Graff JT, Graff JM, **Wakabayashi T, Regillo C**, Maass KF, Callaway N, Gune S, Campochiaro PA. Exudation in Patients with Neovascular Age-Related Macular Degeneration Treated with the Port Delivery System or Monthly Injections. *Am J Ophthalmol*. 2023 Jul 13:S0002-9394(23)00281-7. doi: 10.1016/j.ajo.2023.07.003. Epub ahead of print. PMID: 37453472. <https://pubmed.ncbi.nlm.nih.gov/37453472/>

Awh KC, Mahmoudzadeh R, Salabati M, Mansour HA, Bechay J, Magagna J, Regillo CD, Ho AC, Garg SJ, Hsu J. Outcomes of Intentionally Suspending Treatment in Eyes with Advanced Neovascular Age-Related Macular Degeneration. *Am J Ophthalmol*. 2023 Jul 28:S0002-9394(23)00301-X. doi: 10.1016/j.ajo.2023.07.022. Epub ahead of print. PMID: 37517527. <https://pubmed.ncbi.nlm.nih.gov/37517527/>

Brown GC, Brown MM, Gierhart D, Olk RJ. Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration. *Ophthalmol Ther.* 2023 Jul 10. doi: 10.1007/s40123-023-00742-9. Epub ahead of print. PMID: 37430077. <https://pubmed.ncbi.nlm.nih.gov/37430077/>

Kempen JH, Newcomb CW, Washington TL, Foster CS, Sobrin L, Thorne JE, Jabs DA, Suhler EB, Rosenbaum JT, Sen HN, Levy-Clarke GA, Nussenblatt RB, Bhatt NP, Lowder CY, Goldstein DA, Leiderman YI, Acharya NR, Holland GN, Read RW, **Dunn JP**, Dreger KA, Artornsombudh P, Begum HA, Fitzgerald TD, Kothari S, Payal AR, Daniel E, Gangaputra SS, Kaçmaz RO, Liesegang TL, Pujari SS, Khachatryan N, Maghsoudlou A, Suga HK, Pak CM, Helzlsouer KJ, Buchanich JM; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group.. Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality. *Ophthalmology.* 2023 Jul 25:S0161-6420(23)00519-5. doi: 10.1016/j.ophtha.2023.07.023. Epub ahead of print. PMID: 37499954. <https://pubmed.ncbi.nlm.nih.gov/37499954/>

Qureshi MB, Lentz PC, Xu TT, White LJ, Olsen TW, **Pulido JS**, Dalvin LA. Choroidal Nevus Features Associated with Subspecialty Referral. *Ophthalmol Retina.* 2023 Jul 28:S2468-6530(23)00357-3. doi: 10.1016/j.oret.2023.07.022. Epub ahead of print. PMID: 37517800. <https://pubmed.ncbi.nlm.nih.gov/37517800/>

Salabati M, Massenzio E, Kim J, Awh K, Anderson H, Mahmoudzadeh R, Wakabayashi T, Hsu J, Garg S, Ho AC, Khan MA. Primary Retinal Detachment Repair in Eyes Deemed High Risk for Proliferative Vitreoretinopathy: Surgical Outcomes in 389 Eyes. *Ophthalmol Retina.* 2023 Jul 13:S2468-6530(23)00311-1. doi: 10.1016/j.oret.2023.07.009. Epub ahead of print. PMID: 37453482. <https://pubmed.ncbi.nlm.nih.gov/37453482/>

Schmetterer L, Tezel G, **Schuman J.** Neville Osborne - Editor-in-Chief of Progress in Retinal and Eye Research for 40 years. *Prog Retin Eye Res.* 2023 Jul 19;96:101194. doi: 10.1016/j.preteyeres.2023.101194. Epub ahead of print. PMID: 37473797. <https://pubmed.ncbi.nlm.nih.gov/37473797/>

Soleimani M, Baharnoori SM, Cheraqpour K, **Momenaei B**, Mirshahi R, Chow C, Shahjahan S, Nguyen T, Ashraf MJ, Huang X, Koganti R, Cheraghpour M, Ghassemi M, Djalilian AR. Cellular senescence implication in mustard keratopathy. *Exp Eye Res.* 2023 Aug;233:109565. doi: 10.1016/j.exer.2023.109565. Epub 2023 Jul 3. PMID: 37406956; PMCID: PMC10392783. <https://pubmed.ncbi.nlm.nih.gov/37406956/>

Wykoff CC, Garweg JG, **Regillo C**, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L, Wang L, Wang Y, Bouillaud E, Brown DM. KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. *Am J Ophthalmol.* 2023 Jul 15:S0002-9394(23)00291-X. doi: 10.1016/j.ajo.2023.07.012. Epub ahead of print. PMID: 37460036. <https://pubmed.ncbi.nlm.nih.gov/37460036/>

UVEITIS

Jabs DA, Sugar EA, Burke AE, Altaweel MM, **Dunn JP**, Gangaputra S, Kempen JH, Pepple KL, Stawell RJ, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes. Am J Ophthalmol. 2023 Jul 3:S0002-9394(23)00261-1. doi: 10.1016/j.ajo.2023.06.023. Epub ahead of print. PMID: 37406846. <https://pubmed.ncbi.nlm.nih.gov/37406846/>